Does smoking impact dopamine neuronal loss in de novo Parkinson disease?

Lee, Yoonju; Oh, Jungsu S; Chung, Seok Jong; Chung, Su Jin; Kim, Soo-Jong; Nam, Chung Mo; Lee, Phil Hyu; Kim, Jae Seung et al. · Ann Neurol · 2017

cross_sectional · Level IV

Where this comes from

Abstract

This study analyzed data from dopamine transporter (DAT) positron emission tomographic scans of 282 male patients with de novo Parkinson disease to investigate whether smoking impacts striatal dopamine neuronal degeneration. Mean DAT activity in the posterior (p = 0.016) and ventral putamen (p = 0.028) was higher in 44 current smokers in comparison to 105 ex-smokers and 133 never-smokers. The severity of baseline motor deficits and the longitudinal increases in levodopa-equivalent doses during follow-up were similar among the 3 groups. These results suggest that current smoking, but not past smoking, protects dopamine neuronal degeneration in the sensorimotor striatum with no additional clinical benefits. Ann Neurol 2017;82:850-854.

Medical subject headings